Differential Immune Microenvironments and Response toImmuneCheckpoint Blockadeamong Molecular Subtypes of Murine Medulloblastoma

Clinical Cancer Research

Volumn 22, Issue 3, 2016, Pages 582-595

  Pham, Christina D ^a,b   Flores, Catherine ^a   Yang, Changlin ^a   Pinheiro, Elaine M ^c   Yearley, Jennifer H ^c   Sayour, Elias J ^a,b   Pei, Yanxin ^d   Moore, Colin ^e   McLendon, Roger E ^b   Huang, Jianping ^a   Sampson, John H ^b   Wechsler Reya, Robert ^e   Mitchell, Duane A ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^e BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD3 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IMMUNOMODULATING AGENT; PD 1 MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN PATCHED 1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; PROTEIN PATCHED;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; C57BL 6 MOUSE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL COUNT; CEREBELLUM TUMOR; CONTROLLED STUDY; DENDRITIC CELL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG RESPONSE; DRUG SCREENING; FLOW CYTOMETRY; LYMPHOCYTIC INFILTRATION; MEDULLOBLASTOMA; MONOTHERAPY; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NEURAL STEM CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR BLOCKING; SUPPRESSOR CELL; SURVIVAL TIME; SYSTEMIC THERAPY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR MODEL; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE MARROW CELL; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; KNOCKOUT MOUSE; LYMPHOCYTE COUNT; METABOLISM; MORTALITY; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS; DISEASE MODELS, ANIMAL; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MEDULLOBLASTOMA; MICE; MICE, KNOCKOUT; MYELOID CELLS; PATCHED RECEPTORS; PHENOTYPE; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, CELL SURFACE; T-LYMPHOCYTE SUBSETS; TUMOR MICROENVIRONMENT;

EID: 84958972827     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0713     Document Type: Article

References (34)

1. Sirachainan N, Nuchprayoon I, Thanarattanakorn P, Pakakasama S, Lusawat A, Visudibhan A, et al. Outcome of medulloblastoma in children treated with reduced-dose radiation therapy plus adjuvant chemotherapy. J Clin Neurosci 2011;18:515-9.
2. Packer RJ, Sposto R, Atkins TE, Sutton LN, Bruce DA, Siegel KR, et al. Quality of life in children with primitive neuroectodermal tumors (medulloblastoma) of the posterior fossa. Pediatr Neurosci 1987;13:169-75.
3. Gururangan S, Krauser J, Watral MA, Driscoll T, Larrier N, Reardon DA, et al. Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro Oncol 2008;10:745-51.
4. Northcott PA, Korshunov A, Pfister SM, Taylor MD. The clinical implications of medulloblastoma subgroups. Nat Rev Neurol 2012;8:340-51.
5. Mitchell DA, Sampson JH. Toward effective immunotherapy for the treatment of malignant brain tumors. Neurotherapeutics 2009;6:527-38.
6. Okamoto Y, Shimizu K, Tamura K, Miyao Y, Yamada M,Matsui Y, et al. An adoptive immunotherapy of patients with medulloblastoma by lymphokine-Activated killer cells (LAK). Acta Neurochir (Wien) 1988;94:47-52.
7. Caruso DA, Orme LM, Neale AM, Radcliff FJ, Amor GM, Maixner W, et al. Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro Oncol 2004;6:236-46.
8. Margol A, Robison N, Gnanachandran J, Hung LT, Kennedy R, Vali M, et al. Tumor associated macrophages in SHH subgroup of medulloblastomas. Clin Cancer Res 2015;21:1457-65.
9. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011;29:1408-14.
10. Goodrich LV,Milenkovic L, Higgins KM, Scott MP. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997;277: 1109-13.
11. Zurawel RH, Allen C, Wechsler-Reya R, Scott MP, Raffel C. Evidence that haploinsufficiency of Ptch leads to medulloblastoma in mice. Genes Chromosomes Cancer 2000;28:77-81.
12. Wetmore C, Eberhart DE, Curran T. The normal patched allele is expressed in medulloblastomas frommice with heterozygous germ-line mutation of patched. Cancer Res 2000;60:2239-46.
13. Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ, et al. An animal model of MYC-driven medulloblastoma. Cancer Cell 2012;21:155-67.
14. Wainwright DA, Chang AL, Dey M, Balyasnikova IV, KimCK, Tobias A, et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res 2014;20: 5290-301.
15. Gabrilovich DI,Nagaraj S.Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
16. Inaba K, Swiggard WJ, Steinman RM, Romani N, Schuler G, Brinster C. Isolation of dendritic cells. Curr Protoc Immunol 2009;Chapter 3:Unit 3 7.
17. Yang ZJ, Ellis T, Markant SL, Read TA, Kessler JD, Bourboulas M, et al. Medulloblastoma can be initiated by deletion of Patched in lineagerestricted progenitors or stem cells. Cancer Cell 2008;14:135-45.
18. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002;99: 12293-7.
19. Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002;109:409-17.
20. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
21. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients withmetastatic melanoma. N Engl J Med 2010;363:711-23.
22. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC,McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
23. Brahmer JR, Tykodi SS, ChowLQ,HwuWJ, Topalian SL,HwuP, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
24. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011;29:2787-94.
25. Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 2013;86: 343-9.
26. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-Agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28: 3167-75.
27. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71.
28. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20: 5064-74.
29. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006;116:2777-90.
30. Abad C, Nobuta H, Li J, Kasai A, Yong WH, Waschek JA. Targeted STAT3 disruption in myeloid cells alters immunosuppressor cell abundance in a murine model of spontaneous medulloblastoma. J Leukoc Biol 2014;95: 357-67.
31. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8.
32. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-20.
33. Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 2012; 488:43-8.
34. Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 2015;520:692-6.